Integrin alpha 1 (ITGA1/CD49a) Drug Discovery Landscape & Assay Solutions

  • By admin
  • 26 Sep 2026
  • Comments

Integrin alpha 1 (ITGA1, CD49a), when paired with the beta 1 subunit (ITGB1), forms the heterodimeric receptor VLA-1 (Very Late Antigen-1). As a primary receptor for collagen (specifically Collagen I and IV) and laminin, VLA-1 plays a pivotal role in cell adhesion, migration, and tissue remodeling. In pathological states, ITGA1 is heavily implicated in tissue fibrosis (renal and hepatic), chronic inflammatory diseases (such as Rheumatoid Arthritis and Inflammatory Bowel Disease), and oncology—particularly as a key marker for pro-inflammatory Tissue-Resident Memory T (Trm) cells. Developing highly selective therapeutics against ITGA1 requires rigorous assay validation to ensure specificity over other collagen-binding integrins like Integrin alpha 2.

TarMart Solution Ecosystem & Related Targets

"Comprehensive reagent toolkit for ITGA1 drug discovery. Select your modality below:"

Component / Network Product Description Product Link
Antigen ITGA1 ECD-Fc Recombinant Protein
High purity (>95%), Endotoxin Controlled (<1 EU/ug). Sequence Verified. HEK293 expressed for native glycosylation. Ideal for solid-phase binding and SPR kinetics.		 View ITGA1 Products
Gene Delivery ITGA1 Promise-ORF / Lentivirus
Full-length human ITGA1 ORF for stable cell line generation. Essential for preserving heterodimeric conformation with endogenous ITGB1 in cell-based functional assays.		 View ITGA1 Products
Benchmark Ab Anti-ITGA1 Recombinant Monoclonal Antibody
Recombinant positive control derived from clinical-stage benchmark sequences (e.g., SAN-300). Sequence verified.		 View ITGA1 Products
Validator ITGA1 siRNA Set
Target-specific siRNA pool for target knockdown verification and assay specificity controls.		 View ITGA1 Products
Related Target A ITGB1 (Integrin beta 1)
Heterodimeric partner of ITGA1. Essential for reconstituting functional VLA-1 receptors in vitro.		 View ITGB1 Products
Related Target B ITGA2 (Integrin alpha 2)
Primary homolog and alternative collagen receptor. Crucial for selectivity counter-screening to prevent off-target platelet aggregation effects.		 View ITGA2 Products
Critical Assay Challenge The TarMart Advantage (Technical Spec)
Conformation-dependent ligand binding HEK293 expressed ITGA1 ECD-Fc preserves native post-translational modifications and divalent cation-binding sites.
Selectivity screening against ITGA2 Recombinant ITGA2 homolog proteins available with verified sequence identity for precise counter-screening panels.
Lack of functional validation controls Sequence-verified clinical benchmark antibodies (based on SAN-300) included as reference controls.
False positives in cell-based assays Sequence-verified siRNA knockdown sets enable robust target specificity validation.

Live ITGA1 R&D Tracker

Market data changes daily. Access the latest global pipeline status directly:

Global Clinical Landscape & Future Outlook

The therapeutic targeting of ITGA1 is undergoing a major shift. Historically focused on chronic inflammatory conditions like Rheumatoid Arthritis and Inflammatory Bowel Disease (via blocking collagen-mediated cell retention), the landscape has expanded significantly into fibro-inflammatory diseases and oncology. The discovery that CD49a (ITGA1) marks highly cytotoxic, tissue-resident memory T (Trm) cells in solid tumors and autoimmune tissues has opened new therapeutic windows. Next-generation R&D is heavily focused on selective monoclonal antibodies that can either deplete pathogenic CD49a+ Trm cells in autoimmune lesions or modulate their activity in the tumor microenvironment. Meanwhile, avoiding cross-reactivity with ITGA2 (which mediates platelet adhesion) remains a critical safety threshold for all clinical candidates.

Competitive Modality & Indication Snapshot

Modality Representative Players Key Indications Critical Assay Need (Why TarMart?)
Monoclonal Antibody (Blocking) Biogen, Salix Pharmaceuticals (SAN-300) Inflammatory Bowel Disease, Rheumatoid Arthritis Ligand-blocking assays (Requires high-purity ITGA1 ECD-Fc and collagen-binding validation)
Trm-Targeting Antibody (Depleting) Academic Medical Centers, Biotech Startups Psoriasis, Vitiligo, Solid Tumors Antibody-Dependent Cellular Cytotoxicity (ADCC) assays (Requires ITGA1-expressing stable cell lines via Lentivirus)
Small Molecule Inhibitors Preclinical discovery programs Renal Fibrosis, Hepatic Fibrosis High-throughput selectivity screening (Requires ITGA1 vs. ITGA2 recombinant protein panels)